


PRODUCT: BAZ2-ICR**ALTERNATE NAME:** 4-(4-(1-methyl-1H-pyrazol-4-yl)-1-(2-(1-methyl-1H-pyrazol-4-yl)ethyl)-1H-imidazol-5-yl)benzotrile; BAZ2ICR**CATALOG NUMBER:** B1865-5,25**AMOUNT:** 5 mg, 25 mg**STRUCTURE:****MOLECULAR FORMULA:** C₂₀H₁₉N₇**MOLECULAR WEIGHT:** 357.41**CAS NUMBER:** 1665195-94-7**APPEARANCE:** White to off-white solid**SOLUBILITY:** DMSO (>15 mg/ml)**PURITY:** ≥98% by HPLC**STORAGE:** Store at -20 °C. Protect from air and light**DESCRIPTION:** BAZ2-ICR is a small molecule inhibitor of BAZ2A (K_d = 109 nM; IC₅₀ = 130 nM) and BAZ2B (K_d = 170 nM; IC₅₀ = 180 nM) bromodomains. It displays 15-fold selectivity for binding BAZ2A/B over CECR2 and >100-fold selectivity over all other bromodomains. BAZ2-ICR has been shown to displace BAZ2 bromodomains in living cells by demonstrating accelerated FRAP recovery at 1 μM in the BAZ2A FRAP assay.**REFERENCES:** Drouin, L., *et al.* (2015). *J. Med. Chem.* **58**, 2553-2559.**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**

A-366 (Cat. No. 2859-1, 5)

AMI-1 (Cat. No. 1943-5, 25)

Aza-2'-deoxycytidine (Cat. No. 1754-10, 50)

BAZ2-ICR (B1865)

5- BIX01294 (Cat. No. 1678-5, 25)

Bromodomain Inhibitor, (+)-JQ1 (Cat. No. 2070-1, 5)

BRD4770 (Cat. No.9525-5, 25)

EZSolution™ (+)-JQ1 (Cat. No. 2091-1)

3-Deazaneplanocin (Cat. No. 2060-250, 1000)

2'-Deoxy-5-fluorocytidine (Cat. No. 2387-50, 250)

EPZ-015666 (Cat. No. 9510-1,5)

EPZ011989 (Cat. Np. B1221-5,25)

Lomeguatrib (Cat. No. 2224-5, 25)

Mivebresib (Cat. No. B1564-5,25)

Nanaomycin A (Cat. No. 2790-5, 25)

RG108 (Cat. No. 1679-10, 30)

SGI-1027 (Cat. No. 2726-5, 25)

UNC0638 (Cat. No. 1933-1, 5)

UNC0642 (Cat. No. 2862-5, 25)

Zebularine (Cat. No. 2225-1,

USAGE: **FOR RESEARCH USE ONLY! Not to be used in humans**